pembrolizumab


( Last Updated : June 21, 2022)
Generic Name:
pembrolizumab
Project Status:
Received
Therapeutic Area:
Triple-negative breast cancer
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0295-000
Call for patient/clinician input closed:
Tumour Type:
Breast
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic TNBC who have not received prior chemotherapy for metastatic disease and whose tumors express PD-L1 (CPS ɥ10) as determined by a validated test
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Pending
Tumour Type:
Breast
Indications:
Pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumors express PD-L1 (Combined Positive Score [CPS] ɥ 10) as determined by a validated test
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open20-May-22
Call for patient/clinician input closed15-Jul-22
Submission received20-Jun-22
Submission accepted